Increased Remission Rates After Long-Term Methimazole Therapy in Patients with Graves' Disease: Results of a Randomized Clinical Trial

被引:73
作者
Azizi, Fereidoun [1 ]
Amouzegar, Atieh [1 ]
Tohidi, Maryam [2 ]
Hedayati, Mehdi [3 ]
Khalili, Davood [2 ,4 ]
Cheraghi, Leila [4 ]
Mehrabi, Yadollah [5 ]
Takyar, Miralireza [1 ]
机构
[1] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Endocrine Res Ctr, POB 19395-4763, Tehran 1985717413, Iran
[2] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Prevent Metab Disorders Res Ctr, Tehran, Iran
[3] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Cellular & Mol Endocrine Res Ctr, Tehran, Iran
[4] Shahid Beheshti Univ Med Sci, Res Inst Endocrine Sci, Dept Epidemiol & Biostat, Tehran, Iran
[5] Shahid Beheshti Univ Med Sci, Sch Publ Hlth & Safety, Dept Epidemiol & Biostat, Tehran, Iran
关键词
long-term; methimazole; Graves' disease; remission rates; ANTITHYROID DRUG-TREATMENT; HYPERTHYROIDISM; EXPOSURE; IODINE; RISK;
D O I
10.1089/thy.2019.0180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Studies differ regarding whether, compared with courses of conventional duration, longer-term antithyroid drug treatment increases frequency of remission in patients with Graves' hyperthyroidism. We prospectively conducted a randomized, parallel-group study comparing relapse rates in patients receiving longer-term versus conventional-length methimazole therapy. We also sought variables associated with relapse following the latter. Methods: We enrolled 302 consecutive patients with untreated first episodes of Graves' hyperthyroidism. After 18-24 months of methimazole, 258 patients (85.4%) were randomized to an additional 36-102-month courses ("long-term group": n = 130; scheduled total time on methimazole: 60-120 months) or discontinuation of methimazole ("conventional group": n = 128). Patients were followed 48 months postmethimazole cessation. We performed Cox proportional hazards modeling to identify factors associated with relapse after conventional courses. Results: Methimazole was given for 95 +/- 22 months in long-term patients and 19 +/- 3 months in the conventional group. Fourteen patients experienced cutaneous reactions and 2 liver enzyme elevations during the first 18 months of treatment; no further methimazole-related reactions were observed despite therapy for up to another 118 months. Hyperthyroidism recurred within 48 months postmethimazole withdrawal in 15% (18/119) of long-term patients versus 53% (65/123) of conventional group patients. In the conventional group, older age, higher triiodothyronine or thyrotropin receptor antibody concentrations, lower thyrotropin concentration, or possession of the rs1879877 CD28 polymorphism or the DQB1-05 HLA polymorphism were independently associated with relapse. Conclusion: Administration of low-dose methimazole for a total of 60-120 months safely and effectively treats Graves' hyperthyroidism, with much higher remission rates than those attained by using conventional 18-24-month courses.
引用
收藏
页码:1192 / 1200
页数:9
相关论文
共 27 条
  • [1] Antithyroid drug regimen for treating Graves' hyperthyroidism
    Abraham, Prakash
    Avenell, Alison
    McGeoch, Susan C.
    Clark, Louise F.
    Bevan, John S.
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2010, (01):
  • [2] ANTITHYROID DRUGS AND GRAVES-DISEASE - A PROSPECTIVE RANDOMIZED EVALUATION OF THE EFFICACY OF TREATMENT DURATION
    ALLANNIC, H
    FAUCHET, R
    ORGIAZZI, J
    MADEC, AM
    GENETET, B
    LORCY, Y
    LEGUERRIER, AM
    DELAMBRE, C
    DERENNES, V
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1990, 70 (03) : 675 - 679
  • [3] Reference limit of thyrotropin (TSH) and free thyroxine (FT4) in thyroperoxidase positive and negative subjects: A population based study
    Amouzegar, A.
    Delshad, H.
    Mehran, L.
    Tohidi, M.
    Khafaji, F.
    Azizi, F.
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2013, 36 (11): : 950 - 954
  • [4] Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine
    Azizi, F
    Ataie, L
    Hedayati, M
    Mehrabi, Y
    Sheikholeslami, F
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 152 (05) : 695 - 701
  • [5] Long-Term Antithyroid Drug Treatment: A Systematic Review and Meta-Analysis
    Azizi, Fereidoun
    Malboosbaf, Ramin
    [J]. THYROID, 2017, 27 (10) : 1223 - 1231
  • [6] A 2013 European survey of clinical practice patterns in the management of Graves' disease
    Bartalena, L.
    Burch, H. B.
    Burman, K. D.
    Kahaly, G. J.
    [J]. CLINICAL ENDOCRINOLOGY, 2016, 84 (01) : 115 - 120
  • [7] Graves' Disease and Toxic Nodular Goiter Are Both Associated with Increased Mortality But Differ with Respect to the Cause of Death: A Danish Population-Based Register Study
    Brandt, Frans
    Thvilum, Marianne
    Almind, Dorthe
    Christensen, Kaare
    Green, Anders
    Hegedus, Laszlo
    Brix, Thomas Heiberg
    [J]. THYROID, 2013, 23 (04) : 408 - 413
  • [8] Antithyroid Drugs-The Most Common Treatment for Graves' Disease in the United States: A Nationwide Population-Based Study
    Brito, Juan P.
    Schilz, Stephanie
    Ospina, Naykky Singh
    Rodriguez-Gutierrez, Rene
    Maraka, Spyridoula
    Sangaralingham, Lindsey R.
    Montori, Victor M.
    [J]. THYROID, 2016, 26 (08) : 1144 - 1145
  • [9] A 2011 Survey of Clinical Practice Patterns in the Management of Graves' Disease
    Burch, Henry B.
    Burman, Kenneth D.
    Cooper, David S.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2012, 97 (12) : 4549 - 4558
  • [10] Eighteen Years of Continuously Sustained Elimination of Iodine Deficiency in the Islamic Republic of Iran: The Vitality of Periodic Monitoring
    Delshad, Hossien
    Amouzegar, Atieh
    Mirmiran, Parvin
    Mehran, Ladan
    Azizi, Fereidoun
    [J]. THYROID, 2012, 22 (04) : 415 - 421